<Version><xmlsource>This XML content was developed by AHRQ's contractor ECRI Institute for the National Quality Measures Clearinghouse (NQMC).</xmlsource><Section SecID="560" OrdBy="10" Name="General"><Field FieldID="11" OrdBy="20" ID="561" Name="Title" Type="text"><FieldValue Value="&lt;div class=&quot;content_title&quot;&gt;Atrial fibrillation: the percentage of patients with atrial fibrillation for whom there is a record of a CHADS&lt;sub&gt;2&lt;/sub&gt; score of 1 who are currently treated with anti-coagulation drug therapy or anti-platelet therapy.&lt;/div&gt;" /></Field><Field FieldID="1" OrdBy="30" ID="562" Name="Source(s)" Type="citation"><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;British Medical Association (BMA) and NHS Employers. 2014/15 general medical services (GMS) contract quality and outcomes framework (QOF): guidance for GMS contract 2014/15. London (UK): British Medical Association, National Health Service Confederation; 2014 Mar. 182 p. &lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /></Field><Field Name ="UMLS Concepts"><FieldValue Value="ICD9CM: Atrial fibrillation  (427.31); Injection of anticoagulant  (99.19)"/><FieldValue Value="MSH: Anticoagulants ; Atrial Fibrillation ; Platelet Aggregation Inhibitors ; Time Factors "/><FieldValue Value="MTH: Anticoagulants ; Anticoagulation Therapy ; Atrial Fibrillation ; Platelet Aggregation Inhibitors "/><FieldValue Value="PDQ: anticoagulation "/><FieldValue Value="SNOMEDCT_US: Administration of anticoagulant ; Anticoagulant ; Anticoagulant therapy ; Antiplatelet agent ; Antiplatelet agent therapy ; Atrial fibrillation ; Congestive heart failure, hypertension, age 75 years or older, diabetes, and previous stroke or transient ischemic attack risk score ; Stroke risk ; Use of anticoagulation "/></Field></Section><Section SecID="563" OrdBy="40" Name="Measure Domain"><Field FieldID="3025" OrdBy="50" ID="564" Name="Primary Measure Domain" Type="picklist-one"><FieldValue Value="Clinical Quality Measures: Process" /></Field><Field FieldID="3026" OrdBy="60" ID="565" Name="Secondary Measure Domain" Type="picklist-one"><FieldValue Value="Does not apply to this measure" /></Field></Section><Section SecID="566" OrdBy="70" Name="Brief Abstract"><Field FieldID="34" OrdBy="80" ID="567" Name="Description" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This measure is used to assess the percentage of patients with atrial fibrillation for whom there is a record of a CHADS&lt;sub&gt;2&lt;/sub&gt; score of 1 who are currently treated with anti-coagulation drug therapy or anti-platelet therapy. &lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="21" OrdBy="90" ID="568" Name="Rationale" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Atrial fibrillation (AF) is a common and significant cause of morbidity and mortality. The age-specific prevalence of AF is rising, presumably due to improved survival of patients with coronary heart disease (CHD) (the commonest underlying cause of AF [Psaty et al., 1997]). One per cent of a typical practice population will be in AF; five per cent of patients aged 65 or over and nine percent of patients aged 75 or over. AF is associated with a five-fold increase in risk of stroke (Wolf, Abbott, &amp;amp; Kannel, 1991).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Refer to Scottish Intercollegiate Guidelines Network (SIGN) clinical guidelines &quot;Cardiac arrhythmias in coronary heart disease&quot; (SIGN Publication No. 94, 2007) and &quot;Antithrombotics: indications and management&quot; (SIGN Publication No. 129, 2013) for further information.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;AF is the most common sustained cardiac arrhythmia and, if left untreated, is a significant risk factor for stroke and other morbidities.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;There is evidence that stroke risk can be substantially reduced by warfarin (approximately 66 per cent risk reduction) and less so by aspirin (approximately 22 per cent risk reduction) (&quot;Risk factors for stroke,&quot; 1994).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;To help clinicians decide which management path to choose, several tools have been developed to estimate the risk of stroke on the basis of clinical factors (National Collaborating Centre for Chronic Conditions, 2006; Fang et al., 2008; Van Staa et al., 2011; Olesen et al., 2011). The scoring system recommended for Quality and Outcomes Framework (QOF) is CHADS&lt;sub&gt;2&lt;/sub&gt;, which is validated and particularly suitable for identifying high-risk AF patients, while also being relatively simple to use (Gage et al., 2001). The CHADS&lt;sub&gt;2&lt;/sub&gt; system is based on the AF Investigators I Study (AFI1) and Stroke Prevention in AF I Study (SPAF1) risk criteria (&quot;Risk factors for stroke,&quot; 1994; Stroke Prevention in Atrial Fibrillation Investigators, 1992).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The revised CHADS&lt;sub&gt;2&lt;/sub&gt; system scores one point, up to a maximum of six, for each of the following risk factors (except previous stroke or transient ischemic attack [TIA], which scores double, hence the &lt;sub&gt;'2'&lt;/sub&gt;):&lt;/p&gt;&#xD;&#xA;&lt;ol&gt;&#xD;&#xA;    &lt;li&gt;C &amp;ndash; Congestive heart failure (HF) (one point) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;H &amp;ndash; Hypertension (one point) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;A &amp;ndash; Age 75 or older (one point) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;D &amp;ndash; Diabetes mellitus (one point) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;S&lt;sub&gt;2&lt;/sub&gt; &amp;ndash; Previous stroke or TIA (two points) &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;A score of zero is classified as low risk, one is moderate risk and two or more is high risk.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Evidence from the Birmingham AF Treatment of the Aged Study (BAFTA) (Mant et al., 2007) and AF Clopidogrel Trial with Irbesartan for Prevention of Vascular Events (ACTIVE-W) (Healey et al., 2008) studies suggests that not only is warfarin more effective than aspirin, but that it is not as unsafe (in terms of risk of serious haemorrhage) as previously thought. For example, in the BAFTA trial, the relative risk (RR) for stroke for patients treated with anti-coagulation versus aspirin was 0.46 (95 per cent confidence interval [CI] 0.26 to 0.79). The same study showed no significant difference in the rate of haemorrhage between the warfarin and aspirin arms of the study (RR 0.88, 95 per cent CI 0.46 to 1.63), which suggested a shift in the balance between the risks and benefits of warfarin compared with aspirin. However, to date no meta-analysis has been identified combining the results of studies comparing the two treatments for the outcome of haemorrhage.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Anti-coagulation would not necessarily be indicated if the episode of AF was an isolated event that was not expected to re-occur (for example, one-off AF with a self-limiting cause).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;This indicator uses the CHADS&lt;sub&gt;2&lt;/sub&gt; risk stratification scoring system to inform treatment options. The use of a risk stratification scoring system is in line with European Society of Cardiology (ESC) guidance that states that 'recommendations for therapy should be based on the presence (or absence) of risk factors for stroke and thromboembolism'.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Where the CHADS&lt;sub&gt;2&lt;/sub&gt; score is 0 (low risk), then the patient can be offered treatment with aspirin (European Heart Rhythm Association et al., 2010). Where the CHADS&lt;sub&gt;2&lt;/sub&gt; score is 1 (moderate risk) then either aspirin or anti-coagulants can be offered.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="3500" OrdBy="100" ID="569" Name="Evidence for Rationale" Type="citation"><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;British Medical Association (BMA) and NHS Employers. 2014/15 general medical services (GMS) contract quality and outcomes framework (QOF): guidance for GMS contract 2014/15. London (UK): British Medical Association, National Health Service Confederation; 2014 Mar. 182 p. &lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;European Heart Rhythm Association, European Association for Cardio-Thoracic Surgery, Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S, Van Gelder IC, Al-Attar N, Hindricks G, Prendergast B, Heidbuchel H, Alfieri O, Angelini A, Atar D, Colonna P, De Caterina R, De Sutter J, Goette A, Gorenek B, Heldal M, Hohloser SH, Kolh P, Le Heuzey JY, Ponikowski P, Rutten FH. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2010 Oct;31(19):2369-429. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20802247&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Fang MC, Go AS, Chang Y, Borowsky L, Pomernacki NK, Singer DE, ATRIA Study Group. Comparison of risk stratification schemes to predict thromboembolism in people with nonvalvular atrial fibrillation. J Am Coll Cardiol. 2008 Feb 26;51(8):810-5. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18294564&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA. 2001 Jun 13;285(22):2864-70. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11401607&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Healey JS, Hart RG, Pogue J, Pfeffer MA, Hohnloser SH, De Caterina R, Flaker G, Yusuf S, Connolly SJ. Risks and benefits of oral anticoagulation compared with clopidogrel plus aspirin in patients with atrial fibrillation according to stroke risk: the atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events  (ACTIVE-W). Stroke. 2008 May;39(5):1482-6. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18323500&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Mant J, Hobbs FD, Fletcher K, Roalfe A, Fitzmaurice D, Lip GY, Murray E, BAFTA investigators, Midland Research Practices Network (MidReC). Warfarin versus aspirin for stroke prevention in an elderly community population  with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet. 2007 Aug 11;370(9586):493-503. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17693178&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;National Collaborating Centre for Chronic Conditions. Atrial fibrillation. National clinical guideline for management in primary and secondary care. London (UK): Royal College of Physicians; 2006. 173 p.  [380 references]&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Olesen JB, Lip GY, Hansen ML, Hansen PR, Tolstrup JS, Lindhardsen J, Selmer C, Ahlehoff O, Olsen AM, Gislason GH, Torp-Pedersen C. Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study. BMJ. 2011;342:d124. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21282258&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Psaty BM, Manolio TA, Kuller LH, Kronmal RA, Cushman M, Fried LP, White R, Furberg CD, Rautaharju PM. Incidence of and risk factors for atrial fibrillation in older adults. Circulation. 1997 Oct 7;96(7):2455-61. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9337224&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials [published erratum appears in Arch Intern Med 1994 Oct 10;154(19):2254]. Arch Intern Med. 1994 Jul 11;154(13):1449-57. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8018000&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;The Stroke Prevention in Atrial Fibrillation Investigators. Predictors of thromboembolism in atrial fibrillation: I. Clinical features of patients at risk. Ann Intern Med. 1992 Jan 1;116(1):1-5. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1727091&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Van Staa TP, Setakis E, Di Tanna GL, Lane DA, Lip GY. A comparison of risk stratification schemes for stroke in 79,884 atrial fibrillation patients in general practice. J Thromb Haemost. 2011 Jan;9(1):39-48. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21029359&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991 Aug;22(8):983-8. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1866765&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /></Field><Field FieldID="3022" OrdBy="110" ID="570" Name="Primary Health Components" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Atrial fibrillation; stroke risk assessment; CHADS&lt;sub&gt;2&lt;/sub&gt; risk stratification scoring system; anti-coagulation drug therapy; anti-platelet therapy&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="23" OrdBy="120" ID="571" Name="Denominator Description" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Patients with atrial fibrillation for whom there is a record of a CHADS&lt;sub&gt;2&lt;/sub&gt; score of 1 (see the related &quot;Denominator Inclusions/Exclusions&quot; field)&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="24" OrdBy="130" ID="572" Name="Numerator Description" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Number of patients from the denominator who are currently treated with anti-coagulation drug therapy or anti-platelet therapy (see the related &quot;Numerator Inclusions/Exclusions&quot; field)&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="573" OrdBy="140" Name="Evidence Supporting the Measure"><Field FieldID="3027" OrdBy="150" ID="574" Name="Type of Evidence Supporting the Criterion of Quality for the Measure" Type="picklist-choice"><FieldValue Value="A clinical practice guideline or other peer-reviewed synthesis of the clinical research evidence" /><FieldValue Value="A formal consensus procedure, involving experts in relevant clinical, methodological,  public health and organizational sciences" /><FieldValue Value="One or more research studies published in a National Library of Medicine (NLM) indexed, peer-reviewed journal" /></Field><Field FieldID="3501" OrdBy="160" ID="575" Name="Additional Information Supporting Need for the Measure" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Unspecified&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="3072" OrdBy="180" ID="577" Name="Extent of Measure Testing" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Unspecified&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="580" OrdBy="210" Name="State of Use of the Measure"><Field FieldID="3029" OrdBy="220" ID="581" Name="State of Use" Type="picklist-one"><FieldValue Value="Current routine use" /></Field><Field FieldID="3030" OrdBy="230" ID="582" Name="Current Use" Type="picklist-choice-3"><FieldValue Value="not defined yet" /></Field></Section><Section SecID="583" OrdBy="240" Name="Application of the Measure in its Current Use"><Field FieldID="3031" OrdBy="250" ID="584" Name="Measurement Setting" Type="picklist-choice"><FieldValue Value="Ambulatory/Office-based Care" /></Field><Field FieldID="3032" OrdBy="260" ID="585" Name="Professionals Involved in Delivery of Health Services" Type="picklist-choice-3"><FieldValue Value="not defined yet" /></Field><Field FieldID="3033" OrdBy="270" ID="586" Name="Least Aggregated Level of Services Delivery Addressed" Type="picklist-one"><FieldValue Value="Clinical Practice or Public Health Sites" /></Field><Field FieldID="3505" OrdBy="280" ID="587" Name="Statement of Acceptable Minimum Sample Size" Type="picklist-one"><FieldValue Value="Unspecified" /></Field><Field FieldID="41" OrdBy="290" ID="588" Name="Target Population Age" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Unspecified&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="42" OrdBy="300" ID="589" Name="Target Population Gender" Type="picklist-one"><FieldValue Value="Either male or female" /></Field></Section><Section SecID="660" OrdBy="310" Name="National Strategy for Quality Improvement in Health Care"><Field FieldID="3522" OrdBy="320" ID="661" Name="National Quality Strategy Aim" Type="text"><FieldValue Value="&lt;ul&gt;&lt;li&gt;Better Care&lt;/li&gt;&lt;/ul&gt;" /></Field><Field FieldID="3525" OrdBy="330" ID="662" Name="National Quality Strategy Priority" Type="text"><FieldValue Value="&lt;ul&gt;&lt;li&gt;Prevention and Treatment of Leading Causes of Mortality&lt;/li&gt;&lt;/ul&gt;" /></Field></Section><Section SecID="590" OrdBy="340" Name="Institute of Medicine (IOM) National Health Care Quality Report Categories"><Field FieldID="3163" OrdBy="350" ID="591" Name="IOM Care Need" Type="picklist-choice"><FieldValue Value="Living with Illness" /></Field><Field FieldID="3164" OrdBy="360" ID="592" Name="IOM Domain" Type="picklist-choice"><FieldValue Value="Effectiveness" /></Field></Section><Section SecID="593" OrdBy="370" Name="Data Collection for the Measure"><Field FieldID="3506" OrdBy="380" ID="594" Name="Case Finding Period" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The reporting year&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="3054" OrdBy="390" ID="595" Name="Denominator Sampling Frame" Type="picklist-one"><FieldValue Value="Patients associated with provider" /></Field><Field FieldID="3057" OrdBy="400" ID="598" Name="Denominator (Index) Event or Characteristic" Type="picklist-choice"><FieldValue Value="Clinical Condition" /><FieldValue Value="Diagnostic Evaluation" /></Field><Field FieldID="3058" OrdBy="410" ID="599" Name="Denominator Time Window" Type="picklist-choice-3"><FieldValue Value="not defined yet" /></Field><Field FieldID="55" OrdBy="420" ID="596" Name="Denominator Inclusions/Exclusions" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Inclusions&lt;/strong&gt;&lt;br /&gt;&#xD;&#xA;Patients with atrial fibrillation for whom there is a record of a CHADS&lt;sub&gt;2&lt;/sub&gt; score of 1 &lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Exclusions&lt;/strong&gt;&lt;br /&gt;&#xD;&#xA;Unspecified&lt;/p&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;&lt;strong&gt;Note&lt;/strong&gt;: Exception reporting applies to indicators in any domain of the Quality and Outcomes Framework (QOF), where the achievement is determined by the percentage of patients receiving the specified level of care.&lt;/p&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;&quot;Exceptions&quot; relate to registered patients who are on the relevant disease register or in the target population group and would ordinarily be included in the indicator denominator, but who are excepted by the contractor on the basis of one or more of the exception criteria. Patients are removed from the denominator and numerator for an indicator if they have been both excepted and they have not received the care specified in the indicator wording. If the patient has been excepted but subsequently the care has been carried out within the relevant time period, the patient will be included in both the denominator and the numerator (achievement will always override an exception).&lt;/p&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;Patients may be excepted if they fall within the strict criteria detailed below:&lt;/p&gt;&#xD;&#xA;&lt;ol class=&quot;Note&quot; style=&quot;list-style-type: upper-alpha;&quot; start=&quot;1&quot;&gt;&#xD;&#xA;    &lt;li&gt;Patients who have been recorded as refusing to attend review who have been invited on at least three occasions during the financial year to which the achievement payments relate (except in the case of indicator CS002, where the patient should have been invited on at least three occasions during the period of time specified in the indicator during which achievement is to be measured [e.g., the preceding five years ending on 31 March in the financial year to which achievement payments relate]). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Patients for whom it is not appropriate to review the chronic disease parameters due to particular circumstances, for example, a patient who has a terminal illness or is extremely frail. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Patients newly diagnosed or who have recently registered with the contractor who should have measurements made within three months and delivery of clinical standards within nine months, e.g., blood pressure or cholesterol measurements within target levels. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Patients who are on maximum tolerated doses of medication whose levels remain sub-optimal. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Patients for whom prescribing a medication is not clinically appropriate, e.g., those who have an allergy, contraindication or have experienced an adverse reaction. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Where a patient has not tolerated medication. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Where a patient does not agree to investigation or treatment (informed dissent) and this has been recorded in their patient record following a discussion with the patient. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Where the patient has a supervening condition which makes treatment of their condition inappropriate, e.g., cholesterol reduction where the patient has liver disease. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Where an investigative service or secondary care service is unavailable. &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;Refer to the original measure documentation for further details.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="3507" OrdBy="430" ID="597" Name="Exclusions/Exceptions" Type="picklist-choice-4"><FieldValue Value="not defined yet" /></Field><Field FieldID="59" OrdBy="440" ID="600" Name="Numerator Inclusions/Exclusions" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Inclusions&lt;/strong&gt;&lt;br /&gt;&#xD;&#xA;Number of patients from the denominator who are currently treated* with anti-coagulation drug therapy or anti-platelet therapy&lt;/p&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;*Patients are considered to be 'currently treated' with a specified medicine if they have had a prescription for that medicine within the preceding six months ending on the last day of the financial year to which the achievement payments relate.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Exclusions&lt;/strong&gt;&lt;br /&gt;&#xD;&#xA;Unspecified&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="3061" OrdBy="450" ID="601" Name="Numerator Search Strategy" Type="picklist-one"><FieldValue Value="Fixed time period or point in time" /></Field><Field FieldID="3062" OrdBy="460" ID="602" Name="Data Source" Type="picklist-many"><FieldValue Value="Electronic health/medical record" /><FieldValue Value="Paper medical record" /><FieldValue Value="Registry data" /></Field><Field FieldID="3065" OrdBy="470" ID="603" Name="Type of Health State" Type="picklist-one"><FieldValue Value="Does not apply to this measure" /></Field><Field FieldID="3066" OrdBy="480" ID="604" Name="Instruments Used and/or Associated with the Measure" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;CHADS&lt;sub&gt;2&lt;/sub&gt; Risk Stratification Scoring System&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="605" OrdBy="490" Name="Computation of the Measure"><Field FieldID="3508" OrdBy="500" ID="606" Name="Measure Specifies Disaggregation" Type="picklist-one"><FieldValue Value="Does not apply to this measure" /></Field><Field FieldID="3067" OrdBy="520" ID="608" Name="Scoring" Type="picklist-many"><FieldValue Value="Rate/Proportion" /></Field><Field FieldID="3068" OrdBy="530" ID="609" Name="Interpretation of Score" Type="picklist-one"><FieldValue Value="Desired value is a higher score" /></Field><Field FieldID="3090" OrdBy="540" ID="610" Name="Allowance for Patient or Population Factors" Type="picklist-choice-3"><FieldValue Value="not defined yet" /></Field><Field FieldID="3070" OrdBy="560" ID="612" Name="Standard of Comparison" Type="picklist-choice-3"><FieldValue Value="not defined yet" /></Field><Field FieldID="71" OrdBy="570" ID="613" Name="Prescriptive Standard" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Achievement thresholds: 57% to 97%&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="9" OrdBy="580" ID="614" Name="Evidence for Prescriptive Standard" Type="citation"><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;British Medical Association (BMA) and NHS Employers. 2014/15 general medical services (GMS) contract quality and outcomes framework (QOF): guidance for GMS contract 2014/15. London (UK): British Medical Association, National Health Service Confederation; 2014 Mar. 182 p. &lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /></Field></Section><Section SecID="615" OrdBy="590" Name="Identifying Information"><Field FieldID="73" OrdBy="600" ID="616" Name="Original Title" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;AF004. In those patients with atrial fibrillation in whom there is a record of a CHADS&lt;sub&gt;2&lt;/sub&gt; score of 1, the percentage of patients who are currently treated with anti-coagulation drug therapy or anti-platelet therapy.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="74" OrdBy="610" ID="617" Name="Measure Collection Name" Type="text"><FieldValue Value="Quality and Outcomes Framework Indicators" /></Field><Field FieldID="75" OrdBy="620" ID="618" Name="Measure Set Name" Type="text"><FieldValue Value="Atrial Fibrillation (AF)" /></Field><Field FieldID="16" OrdBy="650" ID="621" Name="Submitter" Type="orglist"><FieldValue Value="British Medical Association - Medical Specialty Society" /><FieldValue Value="National Health Service (NHS) Confederation - National Government Agency [Non-U.S.]" /></Field><Field FieldID="17" OrdBy="660" ID="622" Name="Developer" Type="orglist-p"><FieldValue Value="British Medical Association - Medical Specialty Society" /><FieldValue Value="National Health Service (NHS) Confederation - National Government Agency [Non-U.S.]" /></Field><Field FieldID="79" OrdBy="670" ID="623" Name="Funding Source(s)" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The expert panel who developed the indicators were funded by the English Department of Health.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="80" OrdBy="680" ID="624" Name="Composition of the Group that Developed the Measure" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The main indicator development group is based in the National Primary Care Research and Development Centre in the University of Manchester. They are: Professor Helen Lester, NPCRDC, MB, BCH, MD; Dr. Stephen Campbell, NPCRDC, PhD; Dr. Umesh Chauhan, NPCRDC, MB, BS, PhD.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Others involved in the development of individual indicators are: Professor Richard Hobbs, Dr. Richard McManus, Professor Jonathan Mant, Dr. Graham Martin, Professor Richard Baker, Dr. Keri Thomas, Professor Tony Kendrick, Professor Brendan Delaney, Professor Simon De Lusignan, Dr. Jonathan Graffy, Dr. Henry Smithson, Professor Sue Wilson, Professor Claire Goodman, Dr. Terry O'Neill, Dr. Philippa Matthews, Dr. Simon Griffin, Professor Eileen Kaner.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="81" OrdBy="690" ID="625" Name="Financial Disclosures/Other Potential Conflicts of Interest" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;None for the main indicator development group.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="82" OrdBy="700" ID="626" Name="Endorser" Type="orglist"><FieldValue Value="National Health Service - National Government Agency [Non-U.S.]" /></Field><Field FieldID="19" OrdBy="730" ID="629" Name="Adaptation" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This measure was not adapted from another source.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="3086" OrdBy="740" ID="630" Name="Date of Most Current Version in NQMC" Type="date"><FieldValue Value="2014 Mar" /></Field><Field FieldID="3511" OrdBy="750" ID="631" Name="Measure Maintenance" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Unspecified&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="3512" OrdBy="760" ID="632" Name="Date of Next Anticipated Revision" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Unspecified&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="20" OrdBy="770" ID="633" Name="Measure Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This is the current release of the measure.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;This measure updates a previous version: British Medical Association (BMA) and NHS Employers. Quality and outcomes framework guidance for GMS contract 2013/14. London (UK): British Medical Association, National Health Service Confederation; 2013 Mar. 203 p. &lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="14" OrdBy="780" ID="634" Name="Measure Availability" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The individual measure, &quot;AF004. In Those Patients with Atrial Fibrillation in Whom There Is a Record of a CHADS&lt;sub&gt;2&lt;/sub&gt; Score of 1, the Percentage of Patients Who Are Currently Treated with Anti-coagulation Drug Therapy or Anti-platelet Therapy,&quot; is published in the &quot;2014/15 General Medical Services (GMS) Contract Quality and Outcomes Framework (QOF): Guidance for GMS Contract 2014/15.&quot; This document is available from the &lt;a href=&quot;http://bma.org.uk/-/media/files/pdfs/practical%20advice%20at%20work/contracts/gpqofguidance2014-15.pdf&quot; title=&quot;BMA Web site&quot;&gt;British Medical Association Web site&lt;/a&gt;.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="87" OrdBy="800" ID="636" Name="NQMC Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This NQMC summary was completed by ECRI Institute on July 22, 2013. &lt;/p&gt;&#xD;&#xA;&lt;p&gt;This NQMC summary was updated by ECRI Institute on June 16, 2014.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="88" OrdBy="810" ID="637" Name="Copyright Statement" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;No copyright restrictions apply. &lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="641" OrdBy="850" Name="Production"><Field FieldID="1" OrdBy="1366" ID="562" Name="Source(s)" Type="citation"><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;British Medical Association (BMA) and NHS Employers. 2014/15 general medical services (GMS) contract quality and outcomes framework (QOF): guidance for GMS contract 2014/15. London (UK): British Medical Association, National Health Service Confederation; 2014 Mar. 182 p. &lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /></Field></Section><Section SecID="99999" OrdBy="99999" Name="Disclaimer"><Field FieldID="99999" OrdBy="99999" ID="99999" Name="NQMC Disclaimer" Type="text"><FieldValue Value="&lt;p&gt;The National Quality Measures Clearinghouse™ (NQMC) does not develop, produce, approve, or endorse the measures represented on this site.&lt;/p&gt; &lt;p&gt;All measures summarized by NQMC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public and private organizations, other government agencies, health care organizations or plans, individuals, and similar entities.&lt;/p&gt; &lt;p&gt;Measures represented on the NQMC Web site are submitted by measure developers, and are screened solely to determine that they meet the NQMC Inclusion Criteria which may be found at &lt;a href=&quot;../about/inclusion-criteria.aspx&quot;&gt;http://www.qualitymeasures.ahrq.gov/about/inclusion-criteria.aspx&lt;/a&gt;.&lt;/p&gt; &lt;p&gt;NQMC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or its reliability and/or validity of the quality measures and related materials represented on this site. Moreover, the views and opinions of developers or authors of measures represented on this site do not necessarily state or reflect those of NQMC, AHRQ, or its contractor, ECRI Institute, and inclusion or hosting of measures in NQMC may not be used for advertising or commercial endorsement purposes.&lt;/p&gt; &lt;p&gt;Readers with questions regarding measure content are directed to contact the measure developer.&lt;/p&gt;" /></Field></Section></Version>
